INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO

Group 1 - Pomerantz LLP is investigating claims on behalf of investors of Soleno Therapeutics, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers [1] - Scorpion Capital published a report on August 15, 2025, labeling Soleno's product Vykat XR as overpriced and potentially unsafe for children, leading to a significant stock price drop [3] - Following the Scorpion report, Soleno's stock price decreased by $5.73 per share, or 7.41%, closing at $71.63 per share on the same day [3] Group 2 - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for victims of securities fraud [4]